Oxycodone

6Node page

what any key link opens

psx:substance/oxycodone/proposal/duration/72eef0f9-172a-4a7f-9d58-b8e41da94509

proposal2026-04-27recordapproved

derived from · upstream

none recorded

feeds · downstream

derived_fromvalue/duration/oral/total@1psx:substance/oxycodone/value/duration/oral/total@1

psx:substance/oxycodone/proposal/duration/72eef0f9-172a-4a7f-9d58-b8e41da94509
└─ derived_from  value/duration/oral/total@1

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

5445 with DOI

28 strong · 22 moderate · 4 weak

Compilations

12026-04-27T23:28:09.792Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

62last ruled 2026-06-04

1 awaiting a ruling

Issued documents

42026-10-19T20:33:27.325Z

notice · info card · emergency

Searches

241 with no results

queries and counts on the build

Claims checked

2102 supported

2 supported · 208 not

Correspondence

0received

consent field ships in Phase 4

Edges

572

derivations recorded for this entity

Complete over 54 sources, 1 compilation, and 62 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/oxycodone/archive

2Build

one panel per compilation run

generation run 2026-04-27

61 min completedmodel pipeline-v5plan not recordedrun/d439b974…

Selection

results seen124

selected by the model47

consumed as sources54

Verification

claims checked210

supported2

partially supported0

not supported1

inconclusive207

record
seen / partial
working

The model's own caveats

taper_protocol_is_class_level
clonidine_adjunct_preclinical_only

1 further caveat recorded as free text — readable on the working page

Reproduce

inputs: 54 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

24 searches — query, source, results, what was kept and why

24 searches for this run
#	source	query	seen	kept	rationale
1	PubMed	oxycodone pharmacokinetics bioavailability half-life metabolism CYP	1	1	—
2	PubMed · absence	oxycodone history synthesis Martin Freund Edmund Speyer 1916	0	—	—
3	OpenAlex	oxycodone pharmacology mechanism action opioid receptor	10	3	—
4	OpenAlex	oxycodone opioid epidemic prescription abuse overdose	8	4	—
5	PubMed	oxycodone overdose toxicity mortality respiratory depression	3	2	—
6	PubChem	oxycodone	1	1	—
7	ClinicalTrials.gov	oxycodone pain treatment	10	—	—
8	PubMed	oxycodone dependence withdrawal physical psychological addiction abuse	5	3	—
9	PubMed	oxycodone pharmacology receptor binding mu opioid kappa opioid	9	6	—
10	PubMed	opioid metabolism review	1	1	—
11	Britannica/Web	oxycodone properties history legal status	1	—	—
12	PubMed	oxycodone opioid withdrawal syndrome treatment naloxone precipitated	8	2	—
13	PubMed	oxycodone bioavailability oral intranasal intravenous routes	2	1	—
14	PubMed	oxycodone CYP2D6 CYP3A4 metabolism oxymorphone noroxycodone	10	5	—
15	Web	oxycodone legal status scheduling UK Australia Canada controlled substance	10	4	—
16	PubMed	OxyContin reformulation abuse deterrent extended release oxycodone	8	3	—
17	Web	oxycodone synthesis history 1916 Freund Speyer thebaine Germany	10	1	—
18	PubMed	oxycodone drug interaction alcohol benzodiazepine CNS depressant	5	2	—
19	PubMed	oxycodone serotonin norepinephrine antidepressant interaction	3	2	—
20	ChemicalBook/Web	oxycodone physicochemical properties	1	1	—
21	PubMed	gabapentin pregabalin opioid respiratory depression overdose interaction risk	2	2	—
22	OpenAlex	oxycodone addiction opioid use disorder treatment outcomes	5	2	—
23	Web	oxycodone physicochemical DrugBank Ki values binding affinity	10	—	Used available PubMed data instead (Olson 2019, Nielsen 2007) for receptor binding characterization
24	StatPearls/NCBI	oxycodone pharmacology	1	1	—

210 claims by section — every cited sentence, checked against its source

safety68 · 1 ok

Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Gabapentinoids (pregabalin, gabapentin) co-prescription with opioids significantly increases the risk of opioid-related death in population-based studiessupported
Population-based nested case-control study: co-prescription of gabapentin with opioids significantly increases risk of opioid-related death. journal.pmed.1002396
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →

pharmacology44 · 0 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →

summary30 · 0 ok

Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →

pharmacokinetic-detail14 · 0 ok

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

history12 · 1 ok

Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
US opioid overdose deaths increased from approximately 4,000 in 1999 to over 47,000 in 2017, with prescription opioids — including oxycodone — implicated as the primary driver of the initial surge.supported
Among 70,237 drug overdose deaths in 2017, 47,600 (67.8%) involved an opioid. Since 2013, driven largely by illicitly manufactured fentanyl, current wave marked by increases in synthetic opioid deaths. mmwr.mm675152e1
Claim in history — not_supportednot supportedworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →

clinical-evidence10 · 0 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →

receptor-pharmacology10 · 0 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

comparative-pharmacology8 · 0 ok

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

neuroscience8 · 0 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →

chemistry4 · 0 ok

Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →

effects-overview2 · 0 ok

Claim in effects-overview — inconclusiveinconclusiveworking →
Claim in effects-overview — inconclusiveinconclusiveworking →

3Sources

54 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
year	source	tier	status	feeds
2026	Mu Receptors (StatPearls/NCBI)Herman TF, Cascella M, Muzio MR, et al. · Pharmacology, Biochemistry and Behavior (via StatPearls)pmid:31855381	moderate	consumed	3 sections
2026	Prescription of Controlled Substances: Benefits and RisksPreuss CV, Kalava A, King KC, et al. · Neurology internationaldoi:10.3390/neurolint13040059	moderate	consumed	1 section
2025	Cannabidiol interactions with oxycodone analgesia in an operant orofacial cutaneous thermal pain assayBrice-Tutt AC, Murphy NP, Setlow B, et al. · Pharmacology, Biochemistry and Behaviordoi:10.1016/j.pbb.2025.173968	strong	consumed	1 section
2025	Comprehensive Analysis of Strong Opioid Side Effects in Palliative Care Using the SIDER DatabaseHirai R, Kei M, Uesawa Y · Journal of Clinical Medicinedoi:10.3390/jcm14051410	moderate	consumed	1 section
2025	Oxycodone/naloxone PR versus oxycodone PR in advanced cancer (ENhANCE trial)Wong AK, Grobler A, Mendis R, Philip J, Le B · Palliative Medicinedoi:10.1177/02692163251362563	strong	consumed	1 section
2024	Altered Mental Status in an Octogenarian: Serotonin Syndrome from Venlafaxine and OxycodoneErdem S, Damlakhy A, Konja K, Bashar S · Cureusdoi:10.7759/cureus.57403	weak	consumed	1 section
2024	Comparing withdrawal- and anxiety-like behaviors following oral and subcutaneous oxycodone administration in C57BL/6 miceDe Almeida SS, Drinkuth CR, Sartor GC · Behavioural Pharmacologydoi:10.1097/fbp.0000000000000780	strong	consumed	cited only
2024	Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?Wong AK, Vogrin S, Klepstad P, et al. · Pharmacogenomicsdoi:10.1080/14622416.2024.2430161	moderate	consumed	1 section
2024	Oxycodone physicochemical properties (CAS 76-42-6)ChemicalBookurl:48f93c34f9e039f6	weak	consumed	cited only
2024	Oxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural HIV Outbreak in US HistoryDelcher C, Smith AL, Romanelli F, Gaskill L, Surratt HL · Pharmacoepidemiology and Drug Safetydoi:10.1002/pds.70066	moderate	consumed	cited only
2023	Enzalutamide Reduces Oxycodone Exposure in Men with Prostate CancerDetert Oude Weme SEH, Hulskotte LMG, Vervenne WL, et al. · Clinical Pharmacokineticsdoi:10.1007/s40262-023-01255-1	moderate	consumed	1 section
2023	Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuseRodriguez RD, Dailey Govoni T, Rajagopal V, Green JL · Current Medical Research and Opiniondoi:10.1080/03007995.2023.2178080	moderate	consumed	1 section
2023	Oxycodone pharmacology overview (StatPearls/NCBI Bookshelf)Multiple authorsurl:e866fccbb6332ecd	weak	consumed	cited only
2022	A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preferenceIyer V, Woodward TJ, Pacheco R, Hohmann AG · Neuropharmacologydoi:10.1016/j.neuropharm.2021.108925	strong	consumed	3 sections
2022	CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022Dowell D, Ragan K, Jones CM, et al. · MMWR Recommendations and Reportsdoi:10.15585/mmwr.rr7103a1	moderate	consumed	cited only
2022	Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in NewbornsEsposito DB, Huybrechts KF, Werler MM, et al. · JAMA Network Opendoi:10.1001/jamanetworkopen.2022.28588	moderate	consumed	1 section
2022	Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug testsZhu GD, Whitley P, LaRue L, et al. · The Pharmacogenomics Journaldoi:10.1038/s41397-021-00253-5	moderate	consumed	4 sections
2022	Perinatal oxycodone exposure causes long-term sex-dependent changes in weight trajectory and sensory processing in adult miceMinakova E, Mikati MO, Madasu MK, et al. · Psychopharmacologydoi:10.1007/s00213-022-06257-8	strong	consumed	1 section
2021	Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling ApproachJi B, Xue Y, Xu Y, Liu S, Gough AH, Xie XQ, Wang J · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.0c00810	strong	consumed	1 section
2021	Management of Opioid-Induced Constipation and Bowel DysfunctionDe Giorgio R, Zucco FM, Chiarioni G, et al. · Advances in Therapydoi:10.1007/s12325-021-01766-y	moderate	consumed	2 sections
2021	Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid usersMogali S, Askalsky P, Madera G, Jones JD, Comer SD · Pharmacology, Biochemistry and Behaviordoi:10.1016/j.pbb.2021.173241	strong	consumed	1 section
2021	Validation and characterization of oxycodone physical dependence in C57BL/6J miceCarper M, Contreras KM, Walentiny DM, Beardsley PM, Damaj MI · European Journal of Pharmacologydoi:10.1016/j.ejphar.2021.174111	strong	consumed	1 section
2020	Once-Daily Oxycodone Prolonged-Release Tablets Are Resistant to Alcohol-Induced Dose DumpingBurger N, Fraser D, Maritz MA, Faulkner J, Rey H · Clinical and Translational Sciencedoi:10.1111/cts.12737	strong	consumed	1 section
2020	Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactionsRytkönen J, Ranta VP, Kokki M, Kokki H, Hautajärvi H, Rinne V, Heikkinen AT · Biopharmaceutics & Drug Dispositiondoi:10.1002/bdd.2215	strong	consumed	2 sections
2020	The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiationWolff C, Dowd WN, Ali MM, et al. · Addictive Behaviorsdoi:10.1016/j.addbeh.2019.106268	moderate	consumed	cited only
2019	Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioidsOlson KM, Duron DI, Womer D, Fell R, Streicher JM · PLoS ONEdoi:10.1371/journal.pone.0217371	strong	consumed	3 sections
2019	Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatementYou ZB, Bi GH, Galaj E, Kumar V, Cao J, et al. · Neuropsychopharmacologydoi:10.1038/s41386-018-0284-5	strong	consumed	1 section
2019	Updated Clinical Pharmacokinetics and Pharmacodynamics of OxycodoneKinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M · Clinical Pharmacokineticsdoi:10.1007/s40262-018-00731-3	strong	consumed	5 sections
2018	Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017Scholl L, Seth P, Kariisa M, Wilson NO, Baldwin G · MMWR Morbidity and Mortality Weekly Reportdoi:10.15585/mmwr.mm675152e1	moderate	consumed	1 section
2018	Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effectsBaldo BA · Archives of Toxicologydoi:10.1007/s00204-018-2244-6	moderate	consumed	1 section

Show all 55 sources — 25 more

Sources 31 to 55
year	source	tier	status	feeds
2017	Characterization of [3H] oxymorphone binding sites in mouse brain: Quantitative autoradiography in opioid receptor knockout miceYoo JH, Borsodi A, Toth G, Benyhe S, Gaspar R, Matifas A, Kieffer BL, Metaxas A, Kitchen I, Bailey A · Neuroscience Lettersdoi:10.1016/j.neulet.2017.02.002	strong	consumed	1 section
2017	Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferasesRomand S, Spaggiari D, Marsousi N, et al. · Journal of Pharmaceutical and Biomedical Analysisdoi:10.1016/j.jpba.2016.09.024	strong	consumed	1 section
2017	Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control studyGomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W · PLoS Medicinedoi:10.1371/journal.pmed.1002396	moderate	consumed	1 section
2017	Risk to heroin users of polydrug use of pregabalin or gabapentinLyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, Hickman M, Henderson G · Addictiondoi:10.1111/add.13843	moderate	consumed	1 section
2017	Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuseRaleigh MD, Peterson SJ, Laudenbach M, et al. · PLoS ONEdoi:10.1371/journal.pone.0184876	strong	consumed	3 sections
2016	CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.Dowell D, Haegerich TM, Chou R · MMWR Recommendations and Reportsdoi:10.15585/mmwr.rr6501e1	moderate	consumed	cited only
2016	Relationship between Nonmedical Prescription-Opioid Use and Heroin UseCompton WM, Jones CM, Baldwin G · New England Journal of Medicinedoi:10.1056/nejmra1508490	strong	consumed	1 section
2015	Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolismMoody DE, Liu F, Fang WB · Journal of Analytical Toxicologydoi:10.1093/jat/bkv030	strong	consumed	cited only
2015	Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014Wheeler E, Jones TS, Gilbert MK, Davidson PJ · MMWR Morbidity and Mortality Weekly Reportpmid:26086633	moderate	consumed	1 section
2015	Rates of opioid misuse, abuse, and addiction in chronic painVowles KE, McEntee ML, Siyahhan Julnes P, Frohe T, Ney JP · Paindoi:10.1097/01.j.pain.0000460357.01998.f1	strong	consumed	1 section
2015	The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of AddictionKolodny A, Courtwright DT, Hwang CS, et al. · Annual Review of Public Healthdoi:10.1146/annurev-publhealth-031914-122957	strong	consumed	1 section
2015	Trends in Opioid Analgesic Abuse and Mortality in the United StatesDart RC, Surratt HL, Cicero TJ, et al. · New England Journal of Medicinedoi:10.1056/nejmsa1406143	moderate	consumed	1 section
2013	In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitorsMoody DE, Liu F, Fang WB · Journal of Analytical Toxicologydoi:10.1093/jat/bkt060	strong	consumed	1 section
2012	Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteersZacny JP, Paice JA, Coalson DW · Drug and Alcohol Dependencedoi:10.1016/j.drugalcdep.2012.01.023	strong	consumed	1 section
2010	Does co-administration of paroxetine change oxycodone analgesiaLemberg KK, Heiskanen TE, Neuvonen M, et al. · Scandinavian Journal of Paindoi:10.1016/j.sjpain.2009.09.003	strong	consumed	3 sections
2010	Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signalingMelief EJ, Miyatake M, Bruchas MR, Chavkin C · PNASdoi:10.1073/pnas.1000751107	strong	consumed	4 sections
2008	Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert PanelPergolizzi J, Boger RH, Budd K, Dahan A, et al. · Pain Practicedoi:10.1111/j.1533-2500.2008.00204.x	moderate	consumed	2 sections
2007	Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic painNielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT · Paindoi:10.1016/j.pain.2007.03.022	strong	consumed	3 sections
2007	Oxycodone: a pharmacological and clinical reviewOrdóñez Gallego A, González Barón M, Espinosa Arranz E · Clinical & Translational Oncologypmid:17525040	moderate	consumed	7 sections
2004	Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeysBeardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, Harris LS · Experimental and Clinical Psychopharmacologypmid:15301633	strong	consumed	2 sections
2003	Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 casesCone EJ, Fant RV, Rohay JM, et al. · Journal of Analytical Toxicologypmid:12669998	moderate	consumed	2 sections
2001	Morphine and alternative opioids in cancer pain: the EAPC recommendationsHanks GW, De Conno F, Cherny NI, Hanna M, Kalso E · British Journal of Cancerdoi:10.1054/bjoc.2001.1680	strong	consumed	1 section
1997	Pharmacokinetic comparison of intravenous and intranasal administration of oxycodoneTakala A, Kaasalainen V, Seppala T, Kalso E, Olkkola KT · Acta Anaesthesiologica Scandinavicapmid:9062618	strong	consumed	cited only
1916	Oxycodone synthesis history (Freund & Speyer, 1916)Various historical sourcesurl:6424421adc42a45d	weak	consumed	cited only
—	Searched PubMed for "oxycodone history synthesis Martin Freund Edmund Speyer 1916" — no resultsabsence		no results	—

4Docket

one filing per activity — decisions, correspondence, reports

awaiting ruling — 1

dependence · taper2026-07-03

0012026-04-27revisionRevision 1
Initial LLM generation (v5 pipeline, wiki)
psx:substance/oxycodone/version/1
0022026-06-04proposal59 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
59 items in this filing
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · come_up
- timeline · oral · peak
- timeline · oral · plateau
- timeline · oral · resolution
- timeline · oral · afterglow
- timeline · insufflated · onset
- timeline · insufflated · come_up
- timeline · insufflated · peak
- timeline · insufflated · plateau
- timeline · insufflated · resolution
- timeline · insufflated · afterglow
- timeline · intravenous · onset
- timeline · intravenous · come_up
- timeline · intravenous · peak
- timeline · intravenous · plateau
- timeline · intravenous · resolution
- timeline · intravenous · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · oral
- dosage · insufflated
- dosage · intravenous
- duration · oral · onset
- duration · oral · come_up
- duration · oral · peak
- duration · oral · offset
- duration · oral · total
- duration · oral · aftereffects
- duration · insufflated · onset
- duration · insufflated · come_up
- duration · insufflated · peak
- duration · insufflated · offset
- duration · insufflated · total
- duration · insufflated · aftereffects
- duration · intravenous · onset
- duration · intravenous · come_up
- duration · intravenous · peak
- duration · intravenous · offset
- duration · intravenous · total
- duration · intravenous · aftereffects
- contraindication · respiratory
- contraindication · respiratory
- contraindication · other
- contraindication · other
- contraindication · psychiatric
- contraindication · hepatic
- contraindication · renal
- contraindication · pregnancy_breastfeeding
- contraindication · age
- contraindication · metabolic
- contraindication · psychiatric
psx:substance/oxycodone/proposal/dose_tier/b47bdf5c-a1a8-4c4a-b083-70f7606b4bdc
0032026-06-04publicationPublication — backfill
psx:substance/oxycodone/pub/a005318f-e6a8-46bc-bbca-9518d4baf5a3

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
info_card	beb17ef0cb584efdb61eb917…	2026-10-19 20:33	Revision 1	current
emergency	f85b2d2362c98030e2585598…	2026-09-04 04:31	Revision 1	current
info_card	f310e2b88fa461921dbd62fe…	2026-09-04 04:31	Revision 1	superseded2026-10-19
notice	a978f9c7b775413055cd0636…	2026-09-04 04:31	Revision 1	current

Oxycodone

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-04-27

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

awaiting ruling — 1

5Issued documents

research

draft

audit

verify

simplify